Skip to main content

Precision Medicine: Progress and Promise

By September 20, 2018October 20th, 2018Insights

As genomic technologies move from lab to clinic, how can business and government bridge the gap between availability and access?

Dimensions to be addressed:

  • Health system infrastructure
  • Data on clinical and cost effectiveness
  • Lagging insurance models


  • Jay Flatley, Executive Chairman, Illumina, USA.
  • Elisabet de los Pinos Pont, Founder and Chief Executive Officer, Aura Biosciences, USA.
  • Wang Jian, President and Co-Founder, BGI, People’s Republic of China.

Moderated by: – Mariette DiChristina, Editor-in-Chief, Scientific American, USA.



Author stephen

More posts by stephen